Reference
Scheffler M, Di Gion P, Doroshyenko O, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. Clin Pharmacokinet 2011; 50(6): 371–403
Reference
Breccia M, Alimena G. Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients. BioDrugs 2011; 25(3): 147–57
Reference
Natarajan N, Telang S, Miller D, et al. Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma. Drugs 2011; 71(10): 1233–50
Reference
Kalachand R, Hennessy BT, Markman M. Molecular targeted therapy in ovarian cancer: what is on the horizon? Drugs 2011; 71(8): 947–67
Reference
Montero A, Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 2011; 71(11): 1385–96
Reference
Farnier M. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications. Am J Cardiovasc Drugs 2011; 11(3): 145–52
Reference
Carreau V, Girardet JP, Bruckert E. Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: efficacy and tolerability. Pediatr Drugs 2011; 13(4): 267–75
Reference
Deneer VHM, vanHemel NM. Is antiarrhythmic treatment in the elderly different? A review of the specific changes. Drugs Aging 2011; 28(8): 617–33
Reference
Beresford MW. Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy. Pediatr Drugs 2011; 13(3): 161–73
Reference
Ding Q, Luckhardt T, Hecker L, et al. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. Drugs 2011; 71(8): 981–1001
Reference
Parra J, Portilla J, Pulido F, et al. Clinical utility of maraviroc. Clin Drug Investig 2011; 31(8): 527–42
Reference
Nadel S. Genetic susceptibility in sepsis: implications for the pediatric population. Pediatr Drugs 2011; 13(4): 205–8
Reference
Yang S, Khera P, Wahlgren C, et al. Cutaneous anaplastic large-cell lymphoma should be evaluated for systemic involvement regardless of ALK-1 status: case reports and review of literature. Am J Clin Dermatol 2011; 12(3): 203–9
Reference
Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011; 12(4): 259–70
Reference
Glowacki F, Lionet A, Hammelin JP, et al. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. Clin Pharmacokinet 2011; 50(7): 451–9
References
Schneider BP, Li L, Miller K, et al. Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103 [abstract no. 1000]. J Clin Oncol 2011; 29 Suppl. [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=78499 [Accessed 2011 Aug 9]
American Society of Clinical Oncology. Predictive biomarker for taxane-induced neuropathy identified. ASCO Daily News [online]. Available from URL: http://chicago2011.asco.org/ASCODailyNews/genomics.aspx [Accessed 2011 Aug 9]
Yardley DA, Hainsworth JD, Harwin WN, et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial [abstract no. 1103]. J Clin Oncol 2011; 29 Suppl. [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81708 [Accessed 2011 Aug 9]
Inno A, Strippoli A, Nazzicone G, et al. Treatment of HER2-negative metastatic breast cancer (MBC) with bevacizumab (BEV) plus paclitaxel (TXL): a single-center phase II study [abstract no. e11509]. J Clin Oncol 2011; 29 Suppl. [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83730 [Accessed 2011 Aug 9]
Domchek SM, Friebel T, Neuhausen SL, et al. Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? [abstract no. 1501]. J Clin Oncol 2011; 29 Suppl. [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=78834 [Accessed 2011 Aug 9]
American Society of Clinical Oncology. Study suggests no increased breast cancer risk with hormone replacement therapy after risk-reducing salpingo-oophorectomy. ASCO Daily News [online]. Available from URL: http://chicago2011.asco.org/ASCODailyNews/Abstract1501.aspx [Accessed 2011 Aug 9]
Goss PE, Ingle JN, Ales-Martinez J, et al. Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3 — a randomized, placebo-controlled clinical trial [abstract no. LBA504]. J Clin Oncol 2011; 29 Suppl. [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84784 [Accessed 2011 Aug 9]
Crook JM, O’Callaghan CJ, Ding K, et al. A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013) [abstract no. 4514]. J Clin Oncol 2011; 29 Suppl. [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77775 [Accessed 2011 Aug 9]
American Society of Clinical Oncology. Intermittent androgen suppression noninferiority could change treatment of localized prostate cancer. ASCO Daily News [online]. Available from URL: http://chicago2011.asco.org/ASCODailyNews/Abstract4514.aspx [Accessed 2011 Aug 9]
References
de Lima Lopes G. Epidermal growth factor receptor (EGFR) mutation testing and first line treatment with gefitinib is a dominant strategy in the treatment of advanced non-small cell lung cancer (NSCLC) [abstract no. PCN63]. Value Health 2011; 14(3): A166 [online]. Available from URL: http://www.ispor.org/publications/value/JVAL_14-3_final%204-26-2011.pdf [Accessed 2011 Aug 9]
Chen W, Ellis P, Levin L, et al. Cost-effectiveness of epidermal growth factor receptor gene mutation testing in the selection of first-line therapy for patients with advanced non-small cell lung cancer in Ontario [abstract no. PMD19]. Value Health 2011; 14(3): A82 [online]. Available from URL: http://www.ispor.org/publications/value/JVAL_14-3_final%204-26-2011.pdf [Accessed 2011 Aug 9]
Paulden M, Franek J, Pham B, et al. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: a cost-effectiveness analysis of 1000 strategies for the provision of Adjuvant! Online, Oncotype DX and chemotherapy [abstract no. PCN72]. Value Health 2011; 14(3): A167 [online]. Available from URL:http://www.ispor.org/publications/value/JVAL_14-3_final%204-26-2011.pdf [Accessed 2011 Aug 9]
Reference
Australian Government Department of Health and Ageing. Erbitux and other new medicines listed on the PBS [media release]. 2011 Jun 21 [online]. Available from URL: http://www.health.gov.au/internet/ministers/publishing.nsf/Content/mr-yr11-nr-nr123.htm [Accessed 2011 Aug 9]
Reference
European Medicines Agency. European Medicines Agency recommends restricting use of Pandemrix [media release]. 2011 Jul 21 [online]. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/07/human_pha_detail_000034.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d126 [Accessed 2011 Aug 9]
Reference
US FDA. FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm [Accessed 2011 Aug 9]
Rights and permissions
About this article
Cite this article
Journal Watch. Mol Diag Ther 15, 235–245 (2011). https://doi.org/10.1007/BF03256415
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03256415